Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs.
Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, Nakatsura T, Ishizuka Y, Sasaki R, Watanabe J, Saito M, Saeki H, Hayashi T, Arakawa A, Yao T, Kitano S. Onagi H, et al. Among authors: nakayama t. Breast Cancer Res. 2022 Oct 10;24(1):67. doi: 10.1186/s13058-022-01563-7. Breast Cancer Res. 2022. PMID: 36217150 Free PMC article.
Biomarkers for Immune Checkpoint Inhibitors in Melanoma.
Kitano S, Nakayama T, Yamashita M. Kitano S, et al. Among authors: nakayama t. Front Oncol. 2018 Jul 18;8:270. doi: 10.3389/fonc.2018.00270. eCollection 2018. Front Oncol. 2018. PMID: 30073150 Free PMC article. Review.
Immunotherapy for genitourinary tumors.
Nakayama T, Kitano S. Nakayama T, et al. Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Int J Urol. 2019. PMID: 30710374 Review.
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.
Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. Shitara K, et al. Among authors: nakayama t. J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y. J Immunother Cancer. 2019. PMID: 31340866 Free PMC article. Clinical Trial.
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
Ikarashi D, Kitano S, Tsuyukubo T, Takenouchi K, Nakayama T, Onagi H, Sakaguchi A, Yamashita M, Mizugaki H, Maekawa S, Kato R, Kato Y, Sugai T, Nakatsura T, Obara W. Ikarashi D, et al. Among authors: nakayama t. Br J Cancer. 2022 Mar;126(4):606-614. doi: 10.1038/s41416-021-01628-y. Epub 2021 Nov 15. Br J Cancer. 2022. PMID: 34782748 Free PMC article.
Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma.
Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Katsuya Y, et al. Among authors: nakayama t. Front Oncol. 2023 Jan 9;12:966527. doi: 10.3389/fonc.2022.966527. eCollection 2022. Front Oncol. 2023. PMID: 36698400 Free PMC article.
5,203 results